SILVER SPRING
Ocrevus cleared for pediatric multiple sclerosis
- Sponsor
- Genentech $RHHBY
- Drug
- Ocrevus · ocrelizumab
- Indication
- relapsing-remitting multiple sclerosis
FDA approved Ocrevus (ocrelizumab) IV infusion for relapsing-remitting multiple sclerosis in pediatric patients aged 10 and older.
What this means
Ocrevus is an intravenous antibody treatment that targets B cells, a type of immune cell involved in multiple sclerosis. The FDA has now approved its use for children aged 10 and older with relapsing-remitting MS, expanding its previous adult-only label. This decision gives younger patients access to a treatment that could help manage their condition and reduce relapses.